Evotec and HZI join forces in antibiotics discovery
Evotec AG and the Helmholtz Centre for Infection Research (HZI) have joined platforms in order to find novel resistance-breaking antibiotics against Gram-negative bugs.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1551 entries already.
Entries by Thomas Gabrielczyk
First immunotolerant allogenic cell transplants revealed
/in News/by Thomas GabrielczykResearchers for the first time have found a way to prevent immune rejection of allogenic iPSC-derived cell and tissue transplants.
Arvelle Therapeutics raises $180m in Series A financing
/in News/by Thomas GabrielczykSwiss newco Arvelle Therapeutics has baged a $180m (159.1m) series A financing led by LSP. The company licenced the anti-epileptic candidate cenobamate (YKP3089) for $100m (88.4m) upfront from SK Biopharmaceuticals.
Bio-plastics production grows to 7.5 million tonnes
/in News/by Thomas GabrielczykThe market for bio-based building blocks and polymers showed moderate growth to 7.5 million tonnes in 2018 and will grow with a CGAR of 4% by 2023 reports German nova-Institute.
Reprogrammed pancreatic cells cure type I diabetes
/in News/by Thomas GabrielczykSwiss researchers have demonstrated a way to cure type I diabetes without cell transplantation. In model mice the reprogrammed non-islet cells from human pancreas
Industrial biotech hub validates start-up ideas
/in News/by Thomas GabrielczykBiotech Campus Delft, Royal DSM and YES!Delft partner up have launched a Biotech Validation Lab to validate the business concepts of European biotech startups.
uniqure delivers POC for hemophilia B gene therapy
/in News/by Thomas GabrielczykGene therapy uniQure NV (Amsterdam) reported that factor IX levels of patients with severe hemophilia B raised to a mean of 38% of normal 12 weeks after a single injection of AMT-061.
Ose Pharma gets clinical milestone for IL7R antagonist
/in News/by Thomas GabrielczykOse Immunotherapeutics has got the first milestone payment within its 272m deal with Servier inked in 2016.
How stroma cells trigger tumour angiogenesis
/in News/by Thomas GabrielczykAnalyses of the stroma cell proteome have revealed how intratumoral hypoxia triggers the formation of dysfunctional blood vessels that block drugs from entering the tumour and push metastasis.
Jennewein Biotechnologie expands into Chinese market
/in News/by Thomas GabrielczykJennewein Biotechnologie and Asia’s largest dairy company Yili Group have joined forces to develop an innovative infant formula tailored to the Chinese market.